U.S. President Donald Trump has signed an executive order to expand access to in vitro fertilization (IVF), addressing declining birth rates in developed countries. With more couples delaying parenthood, the assisted reproductive technology (ART) market is booming.
Taiwan is emerging as a key player in reproductive medicine, with cutting-edge biotech companies driving innovation:
- Bonraybio (6955.TW) – A total solution for male infertility, improving sperm health and function
- iPreg – Advanced sperm sorting technology to enhance fertilization success
- Inti Labs – Non-invasive egg evaluation for higher implantation rates
- Jamon – Microfluidic chip technology simulating the oviduct environment for better embryo culture
- AB DigiHealth – AI-powered NGS analytics for maternal-fetal health diagnostics
- Sofiva Genomics (6615.TWO) – Comprehensive genetic testing services for reproductive health
- GGA Corp. (4160.TWO) – Genetic testing solutions for embryos, newborns, and adults
How is Taiwan redefining the future of reproductive medicine?
Read the full analysis